Detail akcie Dynavax Tech online

Business Summary: Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company developing and commercializing vaccines to help protect against infectious diseases. The Company has two commercial products: HEPLISAV-B vaccine (Hepatitis B Vaccine (Recombinant), Adjuvanted), and CpG 1018 adjuvant. The HEPLISAV-B vaccine is used for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose in-one-month adult hepatitis B vaccine. CpG 1018 adjuvant is used in HEPLISAV-B and multiple adjuvanted COVID-19 vaccines. The Company is advancing a pipeline of differentiated product candidates that leverage its CpG 1018 adjuvant to develop improved vaccines in indications with unmet medical needs. Its pipeline programs include Shingles vaccine program (Z-1018) and Plague vaccine program. Z-1018 is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.
Financial Summary: BRIEF: For the six months ended 30 June 2025, Dynavax Technologies Corp revenues increased 31% to $163.6M. Net loss totaled $77.4M vs. income of $2.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net loss reflects General and administrative - Balancing v increase of 53% to $44.2M (expense), Bad debt expense increase from $0K to $11M (expense).